A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

Phase 2 Active not recruiting 145 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 injection in patients with moderate to severe plaque psoriasis.

Timeline

Start: 2025-03-28
Primary completion: 2025-11
Completion: 2026-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1139	Unknown	—	—

A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

Summary

Timeline

Drugs

Indications